Ahn, Chang Ho <br/><br/>
Efficacy and safety of gemigliptin, a dipeptidyl peptidase-4 inhibitor, in patients with type 2 diabetes mellitus inadequately controlled with combination treatment of metformin and sulphonylurea: a 24-week, multicentre, randomized, double-blind, placebo-controlled study (TROICA study).  [electronic resource] 

 -  Diabetes, obesity & metabolism  05 2017 
 - 635-643 p.  digital 
<br/><br/> Publication Type: Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1463-1326 
<br/><br/><label>Standard No.: </label>10.1111/dom.12866  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Aged<br/>Diabetes Mellitus, Type 2--blood<br/>Dipeptidyl-Peptidase IV Inhibitors--adverse effects<br/>Double-Blind Method<br/>Drug Monitoring<br/>Drug Resistance<br/>Drug Therapy, Combination--adverse effects<br/>Female<br/>Glycated Hemoglobin--analysis<br/>Humans<br/>Hyperglycemia--prevention & control<br/>Hypoglycemia--chemically induced<br/>Hypoglycemic Agents--adverse effects<br/>Incidence<br/>Male<br/>Metformin--adverse effects<br/>Middle Aged<br/>Piperidones--adverse effects<br/>Pyrimidines--adverse effects<br/>Republic of Korea--epidemiology<br/>Risk<br/>Sulfonylurea Compounds--adverse effects